Enzalutamide, one of the few treatments shown to extend the lives of men with advanced prostate cancer, has been provisionally approved for use on the NHS in England and Wales, NICE have announced today (Friday 18 October 2013) - a decision which could mean extra months of life to countless men.
Owen Sharp, Chief Executive of Prostate Cancer UK, said: ‘This is great news for men. We fought long and hard to have abiraterone, which works in a similar way, available on the NHS. It isn't successful for every man, and we need clinicians to have options at their disposal to do what counts - extend the lives of men with this disease when other options have run out. We need to see NICE confirm this decision as soon as possible and for the SMC to follow their lead.
"The truth is that there are precious few treatments for a condition which not only seriously impinges upon the life of those with advanced disease, but kills one man each hour. This is a victory for these men today. However, we need to keep on leading change, and working with others to see more treatments emerge for the future. Men continue to deserve better."
 This draft decision will now be consulted on until 9 November before NICE make a final announcement on whether the drug is to be licensed.